The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.

The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.

Item
http://www.wikidata.org/entity/Q43785067
Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple MechanismsThe mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transportA phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemiaHigh efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.Small molecule Mcl-1 inhibitors for the treatment of cancer.Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.Venetoclax for the treatment of chronic lymphocytic leukemia.BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.
P2860

The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.

Item
http://www.wikidata.org/entity/Q43785067
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
The role of lymphatic transpor ...... n family inhibitors navitoclax
@nl
type
label
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
The role of lymphatic transpor ...... n family inhibitors navitoclax
@nl
prefLabel
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
The role of lymphatic transpor ...... n family inhibitors navitoclax
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921